Wall Street analysts expect Intec Pharma Ltd (NASDAQ:NTEC) to report earnings of ($0.19) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Intec Pharma’s earnings. Intec Pharma reported earnings of ($0.32) per share in the same quarter last year, which indicates a positive year over year growth rate of 40.6%. The business is expected to report its next quarterly earnings results on Friday, April 6th.
On average, analysts expect that Intec Pharma will report full year earnings of ($1.35) per share for the current fiscal year. For the next fiscal year, analysts forecast that the company will report earnings of ($0.89) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Intec Pharma.
Intec Pharma (NASDAQ:NTEC) last posted its quarterly earnings results on Wednesday, November 15th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.06).
NTEC has been the subject of a number of research analyst reports. Oppenheimer set a $15.00 price target on shares of Intec Pharma and gave the stock a “buy” rating in a report on Monday, December 18th. Zacks Investment Research upgraded shares of Intec Pharma from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Wednesday, November 22nd. Maxim Group set a $8.00 price objective on shares of Intec Pharma and gave the stock a “buy” rating in a research note on Friday, November 17th. Finally, ValuEngine lowered shares of Intec Pharma from a “hold” rating to a “sell” rating in a research note on Thursday, November 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $11.20.
Intec Pharma (NTEC) opened at $5.80 on Tuesday. Intec Pharma has a fifty-two week low of $4.20 and a fifty-two week high of $9.80.
Several large investors have recently added to or reduced their stakes in NTEC. Caxton Corp acquired a new stake in shares of Intec Pharma in the third quarter worth $681,000. Sectoral Asset Management Inc acquired a new stake in Intec Pharma during the third quarter valued at $3,177,000. Finally, Pura Vida Investments LLC acquired a new stake in Intec Pharma during the third quarter valued at $895,000. Hedge funds and other institutional investors own 40.16% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Brokerages Expect Intec Pharma Ltd (NTEC) Will Post Earnings of -$0.19 Per Share” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/20/brokerages-expect-intec-pharma-ltd-ntec-will-post-earnings-of-0-19-per-share.html.
About Intec Pharma
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Get a free copy of the Zacks research report on Intec Pharma (NTEC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.